Eagle Pharmaceuticals is an integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. Co.'s products and product portfolio include: BARHEMSYS® (amisulpride for injection), which is for the treatment of postoperative nausea and vomiting; BYFAVO® (remimazolam for injection), which is indicated for the induction and maintenance of procedural sedation; bendamustine ready-to-dilute (RTD) 500ml solution, infused bendamustine RTD, and bendamustine RTD and infused RTD in Japan for Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma; Ryanodex® (dantrolene sodium) for Malignant Hyperthermia; and EA-114 (fulvestrant) for breast cancer. The EGRX YTD return is shown above.
The YTD Return on the EGRX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether EGRX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the EGRX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|